Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

25.800
+0.4001.57%
Volume:6.72M
Turnover:173.89M
Market Cap:22.50B
PE:27.99
High:26.800
Open:25.300
Low:24.750
Close:25.400
Loading ...

HUTCHMED (China) Ltd: Will Receive $10 Mln Milestone Payment by Its Partner Takeda

THOMSON REUTERS
·
13 Dec 2024

HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla

MT Newswires Live
·
13 Dec 2024

HUTCHMED to Receive Milestone Payment From Takeda Following First European Reimbursement for Fruzaqla® (Fruquintinib)

THOMSON REUTERS
·
13 Dec 2024

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

GlobeNewswire
·
13 Dec 2024

China Grants Hutchmed Breakthrough Designation for Non-Small Cell Lung Cancer Drug

MT Newswires Live
·
12 Dec 2024

HUTCHMED Secures Breakthrough Therapy Designation in China for Lung Cancer Drug Combination

MT Newswires Live
·
12 Dec 2024

BRIEF-Hutchmed (China) Says Breakthrough Therapy Designation For Orpathys And Tagrisso Combination

Reuters
·
12 Dec 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for Orpathys® and Tagrisso® Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy

THOMSON REUTERS
·
12 Dec 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

GlobeNewswire
·
12 Dec 2024

Innovent and HUTCHMED Jointly Announce Nmpa Conditional Approval for Tyvyt® (Sintilimab Injection) in Combination With Elunate® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

THOMSON REUTERS
·
04 Dec 2024

Hutchmed, Іnnovent Biologics Combination Injection Receives Conditional Approval in China

MT Newswires Live
·
03 Dec 2024

HUTCHMED, Innovent Get Conditional Approval in China for ELUNATE With TYVYT to Treat Advanced Endometrial Cancer

MT Newswires Live
·
03 Dec 2024

HUTCHMED (China) Ltd - Phase Iii Confirmatory Study Planned for Fruquintinib and Sintilimab

THOMSON REUTERS
·
03 Dec 2024

- HUTCHMED China Ltd - HUTCHMED and Innovent Announce Elunate Approval

THOMSON REUTERS
·
03 Dec 2024

HUTCHMED and Innovent Jointly Announce Nmpa Conditional Approval for Elunate® (Fruquintinib) in Combination With Tyvyt® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

THOMSON REUTERS
·
03 Dec 2024

Hutchmed's Lung Cancer Drug to Remain in China's National Reimbursement Drug List

MT Newswires Live
·
28 Nov 2024